Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis

We examined the expression pattern of cyclooxygenase‐2 (COX‐2) and c‐kit in uterine smooth muscle neoplasms and tried to determine the role of these markers in differential diagnosis. Archival tissue from 64 patients with uterine smooth muscle neoplasms (20 leiomyomas (LMs), 22 atypical leiomyomas (...

Full description

Saved in:
Bibliographic Details
Published in:APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2007-06, Vol.115 (6), p.726-735
Main Authors: ÇOMUNOĞLU, NIL ÜSTÜNDAGĞ, DURAK, HAYDAR, ÇOMUNOĞLU, CEM, EKICI, A. IŞIN DOĞAN, ÖZKAN, FERDA, AKYILDIZ, ELIF ÜLKER, İLVAN, ŞENNUR, CALAY, ZERRIN, MOLİNAS, NIL
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomarkers, Tumor - blood
c-kit
COX-2
Cyclooxygenase 2 - metabolism
Diagnosis, Differential
Female
Fundamental and applied biological sciences. Psychology
Gene Expression
Humans
Immunohistochemistry
Infectious diseases
Leiomyosarcoma - chemistry
Medical sciences
Microbiology
Proto-Oncogene Proteins c-kit - metabolism
Receptors, Estrogen - analysis
Receptors, Progesterone - analysis
Retrospective Studies
Smooth Muscle Tumor - chemistry
Smooth Muscle Tumor - diagnosis
smooth muscle tumors
Tumors
Uterine Neoplasms - chemistry
Uterine Neoplasms - diagnosis
uterus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We examined the expression pattern of cyclooxygenase‐2 (COX‐2) and c‐kit in uterine smooth muscle neoplasms and tried to determine the role of these markers in differential diagnosis. Archival tissue from 64 patients with uterine smooth muscle neoplasms (20 leiomyomas (LMs), 22 atypical leiomyomas (ALMs), and 22 leiomyosarcomas (LMSs)) was immunostained with antibodies against estrogen (ER) and progesterone receptors (PR), COX‐2 and c‐kit. 7 of 20 LM cases and 5 of 22 ALM cases were immunopositive for COX‐2, whereas none of the LMS cases stained immunopositive (p≤0.05). 4 of 20 LM cases and 5 of 22 ALM cases were immunopositive for c‐kit, whereas 15 of 22 LMS cases showed c‐kit immunopositivity (p≤0.05). In conclusion, very few LMs and ALMs show COX‐2 immunopositivity. LMSs usually do not express COX‐2. COX‐2 expression in smooth muscle tumors is not a prominent feature. Therefore, COX‐2 inhibitors may not be useful in LMS therapy. C‐kit was significantly expressed in uterine LMSs.
ISSN:0903-4641
1600-0463
DOI:10.1111/j.1600-0463.2007.apm_629.x